Cargando…

Dissociating the Clinical Role and Economic Value of Intranasal Esketamine

Detalles Bibliográficos
Autor principal:	Dadiomov, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2020
Materias:	Perspectives on Value
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391094/ https://www.ncbi.nlm.nih.gov/pubmed/31880233 http://dx.doi.org/10.18553/jmcp.2020.26.1.20

Ejemplares similares

The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

The effectiveness and value of aducanumab for Alzheimer’s disease: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Synnott, Patricia G, et al.
Publicado: (2021)

Mavacamten for hypertrophic cardiomyopathy: effectiveness and value: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Beinfeld, Molly, et al.
Publicado: (2022)

The effectiveness and value of tezepelumab for severe asthma: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Rind, David M, et al.
Publicado: (2022)

The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A, et al.
Publicado: (2023)

The effectiveness and value of novel treatments for cystic fibrosis: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A, et al.
Publicado: (2021)

The effectiveness and value of novel acute treatments for migraine: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

Medications for obesity management: Effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Atlas, Steven J, et al.
Publicado: (2023)

Oral treatments for outpatient COVID-19: Effectiveness and value: A Summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2022)

The Effectiveness and Value of Oral Semaglutide for Type 2 Diabetes Mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Fazioli, Katherine T., et al.
Publicado: (2020)

The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy: A Summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Tice, Jeffrey A., et al.
Publicado: (2020)

The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Nikitin, Dmitriy, et al.
Publicado: (2023)

The effectiveness and value of betibeglogene autotemcel for the management of transfusion-dependent beta-thalassemia: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Lancaster, Victoria, et al.
Publicado: (2022)

The Effectiveness and Value of Siponimod for Secondary Progressive Multiple Sclerosis: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Synnott, Patricia G., et al.
Publicado: (2020)

The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review’s Midwest Public Advisory Council
por: Wright, Abigail C, et al.
Publicado: (2023)

The effectiveness and value of belimumab and voclosporin for lupus nephritis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2021)

The effectiveness and value of targeted immune modulators for moderate to severe ulcerative colitis: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum
por: Pandey, Rajshree, et al.
Publicado: (2021)

JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2022)

The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2020)

The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021)

The effectiveness and value of tirzepatide for type 2 diabetes mellitus: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Nikitin, Dmitriy, et al.
Publicado: (2022)

The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2022)

The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease: A Summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Synnott, Patricia G., et al.
Publicado: (2020)

The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2021)

Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value: A Summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council
por: McKenna, Avery, et al.
Publicado: (2023)

The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021)

The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Tice, Jeffrey A, et al.
Publicado: (2021)

Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Beinfeld, Molly, et al.
Publicado: (2021)

Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies
por: Garrison, Louis P, et al.
Publicado: (2021)

Emerging treatments for lupus nephritis: health equity considerations in clinical research and coverage
por: Newman, Terri V, et al.
Publicado: (2021)

The role of intranasal esketamine in treatment-resistant depression
por: Fraga, A., et al.
Publicado: (2021)

Evaluating a Stone of Hope: ICER’s 2019 Review of Treatments for Duchenne Muscular Dystrophy
por: Brandsema, John Frederick
Publicado: (2020)

Add-On Therapies in Cardiovascular Disease: Reviewing ICER’s Report and the Potential Effect on Payers
por: Magness, Jonathan W., et al.
Publicado: (2020)

Importance of Patient-Centered Outcomes When Evaluating Treatments for Secondary Progressive Multiple Sclerosis
por: Taddei-Allen, Patty
Publicado: (2020)

Oral Semaglutide: Balancing Promising Therapeutics with Adverse Effects and Access Barriers
por: Gunning, Karen
Publicado: (2020)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

Peanut Immunotherapy: Stepping Towards Desensitization for Peanut Allergy
por: Hsu, Joyce
Publicado: (2020)

Shifting paradigms: Reframing coverage of antiobesity medications for plan sponsors
por: Green, Libbi, et al.
Publicado: (2023)

Considerations for managed care pharmacy in evaluating mavacamten, a novel agent for obstructive hypertrophic cardiomyopathy
por: Taddei-Allen, Patty
Publicado: (2022)

The potential promise and challenge for tezepelumab as a biologic therapy for severe asthma
por: Williams, Dennis M
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7av3ikpm7beu7p80so9uoa31h9